` EDTXF (Spectral Medical Inc) vs S&P 500 Comparison - Alpha Spread

EDTXF
vs
S&P 500

Over the past 12 months, EDTXF has significantly outperformed S&P 500, delivering a return of +53% compared to the S&P 500's +16% growth.

Stocks Performance
EDTXF vs S&P 500

Loading
EDTXF
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
EDTXF vs S&P 500

Loading
EDTXF
S&P 500
Difference
www.alphaspread.com

Performance By Year
EDTXF vs S&P 500

Loading
EDTXF
S&P 500
Add Stock

Competitors Performance
Spectral Medical Inc vs Peers

S&P 500
EDTXF
ABBV
CYTH
AMGN
GILD
Add Stock

Spectral Medical Inc
Glance View

Market Cap
165.4m USD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDTXF Intrinsic Value
0.03 USD
Overvaluation 95%
Intrinsic Value
Price
Back to Top